KineMed Announces Biomarker Discovery Collaboration With Major Pharma Co.
KineMed, Inc. recently announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize, and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis, and metabolic diseases.
“We are delighted to announce this collaboration,” said David Fineman, President & CEO of KineMed. “The marriage of KineMed’s insights into biology with GSK’s clinical portfolio marks the start of an exceptional initiative to advance innovative evidence-based medicines.”
“Our shared goal with GSK is to identify causal pathways and kinetic signatures that can better inform drug development decisions,” added Marc Hellerstein, MD, PhD, Chief of the Scientific Advisory Board of KineMed. “The missing links in developing drugs to treat muscle wasting, fibrosis, and metabolic diseases have been reliable biomarkers that measure the degree to which we are having therapeutic impact on their underlying disease processes. KineMed’s technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them.”
KineMed, Inc. is a biomarker discovery and development company based in
KineMed’s established, proprietary platform assists pharmaceutical collaborators by revealing the mechanism of action of complex diseases and providing quantitative measures of the effects of drugs on these causal processes. The company’s biomarkers are fully translational from animal to man, seamlessly harmonizing data across preclinical and clinical phases of development, through to the diagnosis and management of disease.
KineMed is seeking further broad collaborations with biotechnology, pharmaceutical, CRO, histopathology, diagnostics, and medical instrument partners. For more information, visit www.kinemed.com.
Total Page Views: 1325
